口服蛋白質和胜肽市場規模、佔有率和成長分析：按給藥途徑、分子類型、應用、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球口服蛋白質和胜肽市場價值為 11.9 億美元，預計到 2025 年將成長至 13.2 億美元，到 2033 年將成長至 828.7 億美元，在預測期（2026-2033 年）內複合年成長率為 11.3%。

全球口服蛋白和胜肽市場涵蓋用於口服給藥的蛋白類治療藥物和胜肽的配方、生產和分銷，為注射型生物製藥提供了一種替代方案，並改善了慢性病和營養需求患者的治療可及性。該市場最初受生物利用度低等挑戰的限制，但封裝技術的創新使其重獲新生，例如，GLP-1類似物等胜肽類藥物能夠耐受胃酸分解。糖尿病盛行率的上升和老齡化人口對口服療法的需求不斷成長，推動了這一發展，並顯著擴大了市場規模。將先進的遞送平台與胜肽類藥物結合，可實現與注射劑相當的療效，同時降低成本並提高患者依從性。此外，策略合作正在提高胜肽的穩定性，為各種慢性病開闢新的治療途徑，並加速市場擴張。人工智慧驅動的自動化透過最佳化配方設計和簡化品管流程，進一步提高了產品開發的效率。

全球口服蛋白質和胜肽市場成長要素

口服療法需求的不斷成長正顯著推動全球口服蛋白和胜肽市場的發展。病患和醫療專業人員越來越傾向於選擇便捷的非注射給藥方式，以提高用藥依從性並減少就診次數。這項轉變促使製藥公司專注於開發適用於口服的高穩定性蛋白和胜肽製劑，從而推動了保護性包衣、吸收促進劑和創新輔料等方面的進步。因此，不斷擴充的口服生物製藥產品平臺和激增的臨床試驗正在強化市場需求，在全球製藥業形成研發與應用不斷成長的良性循環。

全球口服蛋白質和胜肽市場面臨的限制因素

全球口服蛋白和胜肽市場面臨嚴峻的挑戰，這主要歸因於嚴格的監管要求，這些要求強調安全性、有效性和品質標準。這些法規結構通常會延長研發週期，並為企業帶來不確定性。監管機構通常要求提供關於胃腸道穩定性、吸收過程和長期安全性的大量數據，這需要進行額外的臨床前和臨床試驗。這種嚴格的監管不僅推高了成本，也阻礙了中小企業進入市場，最終限制了市場競爭。因此，新產品上市速度放緩，整體市場擴張受到限制，投資者往往更傾向於那些核准相對容易的項目，導致開發平臺的多樣性降低。

口服蛋白質和胜肽市場的全球趨勢

在全球消費者對個人化醫療解決方案的需求推動下，全球口服蛋白和胜肽市場正經歷顯著的變革。製造商們日益專注於開發基於胜肽的口服製劑，以專門解決各種胃腸道和全身健康問題。透過利用胜肽穩定性、包封和靶向釋放技術的進步，企業正在開發與個體基因譜和生活方式相匹配的客製化產品。這種個人化趨勢不僅提高了療效並最大限度地減少了副作用，還增強了品牌忠誠度。優先投資精準口服胜肽的企業正在成為不斷發展的全球醫療保健市場格局中的關鍵參與者。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球口服蛋白質和胜肽市場規模：按給藥途徑分類

• 口服錠劑
• 口服膠囊
• 口服溶液和懸浮液
• 其他

全球口服蛋白質和胜肽市場規模：按分子類型分類

• 蛋白質
• 胜肽

全球口服蛋白質和胜肽市場規模：按應用分類

• 糖尿病
• 消化器官系統疾病
• 荷爾蒙失調
• 代謝性疾病
• 感染疾病
• 其他

全球口服蛋白質和胜肽市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球口服蛋白質和胜肽市場規模：按最終用戶分類

• 醫院
• 專科診所
• 居家醫療

全球口服蛋白質和胜肽市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novo Nordisk AS
• Chiasma Inc
• Myrcludex GmbH
• Biocon Limited
• Oramed Pharmaceuticals Inc
• Rani Therapeutics LLC
• Enteris BioPharma Inc
• Emisphere Technologies Inc
• Synergy Pharmaceuticals Inc
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• AstraZeneca plc
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc
• Hoffmann-La Roche Ltd
• Genentech Inc
• Allergan plc
• Bausch Health Companies Inc
• Proxima

結論與建議

Global Oral Proteins And Peptides Market size was valued at USD 1.19 Billion in 2024 and is poised to grow from USD 1.32 Billion in 2025 to USD 82.87 Billion by 2033, growing at a CAGR of 11.3% during the forecast period (2026-2033).

The Global Oral Proteins and Peptides Market encompasses the formulation, manufacturing, and distribution of protein-based therapeutics and peptides designed for oral administration, providing alternatives to injectable biologics and enhancing access to treatments for chronic diseases and nutritional needs. Market growth, initially hindered by low bioavailability challenges, has been revitalized through innovations in encapsulation techniques, enabling peptides, like GLP-1 analogues, to withstand gastric degradation. This evolution has propelled market value significantly, driven by increasing diabetes prevalence and an aging demographic seeking oral therapies. The integration of advanced delivery platforms with peptide drugs improves therapeutic exposure akin to injections, reducing costs and boosting patient adherence. Additionally, strategic collaborations are enhancing peptide stability, unlocking new therapies for a range of chronic conditions, thereby accelerating market expansion. AI-driven automation further enhances product development efficiency by optimizing formulation design and streamlining quality control processes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oral Proteins And Peptides market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oral Proteins And Peptides Market Segments Analysis

Global oral proteins and peptides market is segmented by route of administration, molecule type, application, distribution channel, end user and region. Based on route of administration, the market is segmented into Oral Tablets, Oral Capsules, Oral Solutions & Suspensions and Others. Based on molecule type, the market is segmented into Proteins and Peptides. Based on application, the market is segmented into Diabetes, Gastrointestinal Disorders, Hormonal Disorders, Metabolic Disorders, Infectious Diseases and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oral Proteins And Peptides Market

The rising demand for orally administered therapeutics significantly propels the growth of the global oral proteins and peptides market. Patients and healthcare providers increasingly favor convenient, non-injection options that enhance adherence while minimizing the need for clinical visits. This shift motivates pharmaceutical companies to focus on developing stable formulations of proteins and peptides that are suitable for oral consumption, leading to advancements in protective coatings, absorption enhancers, and innovative excipients. As a result, an expanding product pipeline and a surge in clinical trials for orally delivered biologics strengthen market demand, creating a dynamic cycle of research, development, and increased adoption within the global pharmaceutical sector.

Restraints in the Global Oral Proteins And Peptides Market

The Global Oral Proteins and Peptides market faces significant challenges due to stringent regulatory requirements that emphasize safety, efficacy, and quality standards. These frameworks often lengthen development timelines and introduce uncertainty for companies. Regulatory agencies commonly demand extensive data regarding gastrointestinal stability, absorption processes, and long-term safety, leading to the need for additional preclinical and clinical trials. This rigorous oversight not only elevates costs but also discourages smaller firms from participating in the market, thereby restricting competitive dynamics. As a consequence, the introduction of new products slows down, limiting overall market expansion, while investors tend to favor projects with more straightforward regulatory approvals, reducing the diversity of the development pipeline.

Market Trends of the Global Oral Proteins And Peptides Market

The Global Oral Proteins and Peptides market is experiencing a significant shift driven by consumer demand for personalized healthcare solutions. Manufacturers are increasingly focused on developing peptide-based oral formulations that specifically address various gastrointestinal and systemic health issues. By harnessing advancements in peptide stability, encapsulation, and targeted release technologies, companies are creating tailored products that cater to individual genetic profiles and lifestyle choices. This trend towards personalization not only enhances therapeutic efficacy and minimizes adverse effects but also fosters brand loyalty. Firms that prioritize investment in precision oral peptides are establishing themselves as key players in the evolving market landscape of global healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oral Proteins and Peptides Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Tablets
• Oral Capsules
• Oral Solutions & Suspensions
• Others

Global Oral Proteins and Peptides Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Proteins
• Peptides

Global Oral Proteins and Peptides Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diabetes
• Gastrointestinal Disorders
• Hormonal Disorders
• Metabolic Disorders
• Infectious Diseases
• Others

Global Oral Proteins and Peptides Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Oral Proteins and Peptides Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care Settings

Global Oral Proteins and Peptides Market Size & CAGR (2026-2033)

• North America (Route of Administration, Molecule Type, Application, Distribution Channel, End User)
  • US
  • Canada
• Europe (Route of Administration, Molecule Type, Application, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Route of Administration, Molecule Type, Application, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Route of Administration, Molecule Type, Application, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Route of Administration, Molecule Type, Application, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiasma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myrcludex GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rani Therapeutics LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enteris BioPharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emisphere Technologies Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synergy Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proxima
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations